NEW YORK, Aug. 18, 2017 -- LifeSci Advisors, LLC (the "Company" or "LifeSci"), the leading international investor relations and corporate communications firm dedicated to the life sciences sector, today announced the appointment of Ashley Robinson as Managing Director. Mr. Robinson will serve as a Relationship Manager and will contribute to Corporate Access.
Ashley Robinson has 20 years of experience in institutional equity sales, with a focus on the healthcare sector. He began his Wall Street career at Lehman Brothers Holdings, Inc., where he spent time in both the New York and Boston offices. Following this, Mr. Robinson spent 14 years at Leerink Partners, LLC, where he was a Managing Director and Partner. At Leerink, Mr. Robinson helped establish and build the institutional franchise, and was responsible for covering the firm’s largest accounts, which allowed him to develop deep relationships with many leading healthcare investors. During his tenure, Mr. Robinson served as “Deal Captain” on most of Leerink’s capital markets transactions, and was the primary liaison between sales and equity capital markets.
Prior to joining LifeSci, Mr. Robinson was the Healthcare Product Specialist and Sector Head at Guggenheim Securities, LLC, where he was responsible for building a research franchise in that sector. Mr. Robinson earned a Bachelor of Arts degree from Hobart College, where he double-majored in Economics and Russian Area Studies.
"We are pleased to add Ashley to our growing team,” said Michael Rice, President and Co-Founder of LifeSci Advisors. “Having served as Deal Captain on most of Leerink’s capital markets transactions during his 14 years at the firm, Ashley is well-connected within the healthcare investment community. In addition, he has a deep understanding of the healthcare industry. As LifeSci’s business continues to grow, we continue to attract leading professionals, like Ashley, to counsel and support our client companies. We look forward to leveraging Ashley’s vast corporate finance expertise and robust network of investor contacts.”
“I am excited to be joining the largest life sciences investor relations firm,” said Mr. Robinson. “LifeSci has established a strong reputation in the healthcare industry, both among companies and within the investment community, and I look forward to leveraging my 20 years of institutional equity sales experience to further advance the firm’s business.”
LifeSci has offices in Israel, UK and Switzerland, as well as multiple North American locations. The firm’s capabilities include Corporate Access, Equity Research, Corporate Communications, KOL Events, Corporate Governance, Capital Markets Solutions, and Public Relations.
LifeSci Advisors, LLC (www.lifesciadvisors.com) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of financial services, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows us to provide a valuable and unique service offering to our clients.
LifeSci Partners (www.lifescipartners.com) is the leading provider of comprehensive consulting services in the areas of investor relations, corporate communications, public relations and capital markets advisory. Combining deep domain expertise in the life sciences and decades of experience in capital markets and public relations, we deliver unparalleled services to life sciences companies globally. LifeSci Partners has a physical presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv.
For further information, please contact: Michael Rice Founding Partner LifeSci Advisors, LLC (646) 597-6979


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure
Tesla Launches New Model Y Variant in the US Starting at $41,990
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 



